×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANIK – anika therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANIK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/4
11:12 pm
anik
Anika Therapeutics, Inc. (NASDAQ: ANIK) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Anika Therapeutics, Inc. (NASDAQ: ANIK) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/1
10:34 am
anik
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target lowered by analysts at Barrington Research from $37.00 to $25.00. They now have an "outperform" rating on the stock.
Low
Report
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target lowered by analysts at Barrington Research from $37.00 to $25.00. They now have an "outperform" rating on the stock.
11/1
07:29 am
anik
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
10/31
11:00 am
anik
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
Medium
Report
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
10/31
07:11 am
anik
Anika Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Anika Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
10/31
07:05 am
anik
Anika Reports Third Quarter 2024 Financial Results
High
Report
Anika Reports Third Quarter 2024 Financial Results
10/31
07:00 am
anik
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
High
Report
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
10/22
10:46 am
anik
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $37.00 price target on the stock.
Low
Report
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $37.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/4
04:41 pm
anik
Form 10-Q Anika Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q Anika Therapeutics, Inc. For: Sep 30
10/31
07:21 am
anik
Form 8-K Anika Therapeutics, Inc. For: Oct 31
High
Report
Form 8-K Anika Therapeutics, Inc. For: Oct 31
10/31
07:16 am
anik
Form 8-K Anika Therapeutics, Inc. For: Oct 31
High
Report
Form 8-K Anika Therapeutics, Inc. For: Oct 31
10/23
05:05 pm
anik
Form SC 13G/A Anika Therapeutics, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Anika Therapeutics, Inc. Filed by: BlackRock, Inc.
10/4
04:07 pm
anik
Form 4 Anika Therapeutics, Inc. For: Oct 01 Filed by: Nunes Anne
Low
Report
Form 4 Anika Therapeutics, Inc. For: Oct 01 Filed by: Nunes Anne
8/8
05:21 pm
anik
Form 10-Q Anika Therapeutics, Inc. For: Jun 30
Neutral
Report
Form 10-Q Anika Therapeutics, Inc. For: Jun 30
8/8
04:11 pm
anik
Form 8-K Anika Therapeutics, Inc. For: Aug 08
Neutral
Report
Form 8-K Anika Therapeutics, Inc. For: Aug 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/24
Q3/2019 9/30/2019 EPS 0.640 ZacksConsensus 0.410 ActVsEst 0.230 - Beat
35.2%
7/24 Q2/2019 6/30/2019 EPS 0.670 ZacksConsensus 0.420 ActVsEst 0.250 - Beat 29.0%
4/8 Anika Therapeutics beefs up liquidity amid COVID-19 disruptions [Seeking Alpha] 9.0%
3/24 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 8.9%
4/28 Form 4 Anika Therapeutics, Inc. For: Apr 26 Filed by: Blanchard Cheryl R 7.9%
5/3 Anika Therapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] 5.9%
1/6 Anika Therapeutics to Acquire Parcus Medical and Arthrosurface 4.6%
4/22 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.6%
4/27 Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer 4.3%
7/25 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock. 3.2%
7/24 Q2/2019 6/30/2019 EPS 0.670 ZacksConsensus 0.420 ActVsEst 0.250 - Beat 29.0%
4/8 Anika Therapeutics beefs up liquidity amid COVID-19 disruptions [Seeking Alpha] 9.0%
3/24 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 8.9%
4/28 Form 4 Anika Therapeutics, Inc. For: Apr 26 Filed by: Blanchard Cheryl R 7.9%
5/3 Anika Therapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] 5.9%
1/6 Anika Therapeutics to Acquire Parcus Medical and Arthrosurface 4.6%
4/22 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.6%
4/27 Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer 4.3%
7/25 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock. 3.2%
TOP News Decliners
3/13
Form 8-K/A Anika Therapeutics, Inc. For: Feb 03
-16.2%
3/18 Form SEC STAFF LETTER Anika Therapeutics, Inc. -11.5%
3/6 Form 3 Anika Therapeutics, Inc. For: Mar 04 Filed by: Colleran David -9.4%
4/29 Form DEF 14A Anika Therapeutics, Inc. For: Jun 16 -7.3%
2/20 Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.0%
3/17 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.8%
1/29 Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer -5.4%
4/27 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock. -4.7%
7/26 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.5%
7/30 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.4%
3/18 Form SEC STAFF LETTER Anika Therapeutics, Inc. -11.5%
3/6 Form 3 Anika Therapeutics, Inc. For: Mar 04 Filed by: Colleran David -9.4%
4/29 Form DEF 14A Anika Therapeutics, Inc. For: Jun 16 -7.3%
2/20 Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.0%
3/17 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.8%
1/29 Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer -5.4%
4/27 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock. -4.7%
7/26 Anika Therapeutics Inc (NASDAQ: ANIK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.5%
7/30 Anika Therapeutics Inc (NASDAQ: ANIK) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: